Cost of managing severe cutaneous adverse drug reactions to first‐line tuberculosis therapy in South Africa
Authors:
- 7 June 2019
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 24 (8) , 994-1002
Abstract
Objective: To compare the cost of managing treatment‐limiting cutaneous adverse drug reactions (CADRs) to first‐line anti‐tuberculosis drugs to an alternative strategy of immediate treatment initiation using second‐line drugs in a South African setting.Methods: Clinical and cost data were retrospectively collected from patients presenting with a first‐line anti‐tuberculosis therapy‐associated CADR. Costs (2016 US$) were estimated using an ingredient’s approach from a healthcare provider perspective. The per‐patient and total cost of drug rechallenge, the current management strategy for severe CADR, was calculated. Alternative strategies involving second‐line treatment were derived from literature and expert clinical advice.Results: Drug rechallenge costs US $5831 (95% CI: 5134–6527) per patient. Hospitalisation accounted for 62% of this cost. Alternative CADR management strategies using regimens containing rifabutin, bedaquiline and/or delamanid cost 44%–55% less than drug rechallenge (US $2651–US $3276/patient). In univariate sensitivity analyses, drug rechallenge and alternative strategies were most sensitive to hospitalisation and tuberculosis drug costs, respectively.Conclusion: Cutaneous adverse drug reactions to anti‐tuberculosis treatment represent a significant economic burden. An alternate strategy of outpatient‐initiated second‐line therapy is economically feasible but requires clinical validation to assess effectiveness.Keywords
This publication has 31 references indexed in Scilit:
- What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?PLOS ONE, 2013
- Costs of inpatient treatment for multi‐drug‐resistant tuberculosis in South AfricaTropical Medicine & International Health, 2012
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- The Impact and Cost of Scaling up GeneXpert MTB/RIF in South AfricaPLOS ONE, 2012
- Cutaneous Adverse Effects of Ketoprofen for Topical UseAmerican Journal of Clinical Dermatology, 2010
- Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment–Induced HepatotoxicityClinical Infectious Diseases, 2010
- New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical DevelopmentAntimicrobial Agents and Chemotherapy, 2009
- Treatment Options for HIV‐Associated TuberculosisThe Journal of Infectious Diseases, 2007
- Activation of the Pro-drug Ethionamide Is Regulated in MycobacteriaJournal of Biological Chemistry, 2000
- A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosisTubercle and Lung Disease, 1995